GLP-1 Medications FDA Guidance and Compounded Products Not long ago, few outside the medical community had heard of semaglutide and tirzepatidetwo drugs in the GLP-1 (glucagon-like peptide-1) receptor agonist class, approved for diabetes management
Gut microbial metabolites of tryptophan augment enteroendocrine cell differentiation in human colonic organoids
Based on Phase 2 clinical trial data, retatrutide is administered as a once-weekly subcutaneous injection, consistent with other long-acting incretin-based therapies such as semaglutide and tirzepatide
A direct comparison study (SURMOUNT-5) further clarified the Wegovy vs Zepbound weight loss percent average at maximum tolerated doses for chronic weight management: Zepbound: Patients achieved an average total body weight loss of 20.2% over 72 weeks
Branded drugs may qualify for employee health plans or Medicare Part D (depending on indication), whereas compounded medications are often out-of-pocket
Mechanism of Action & Pharmacology Retatrutide is classified as a triple-receptor agonist, activating the GLP-1, GIP, and glucagon receptors simultaneously